-
公开(公告)号：US20130164299A1
公开(公告)日：2013-06-27
申请号：US13807505
申请日：2011-06-28
申请人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
发明人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
IPC分类号： C07K16/18
CPC分类号： C07K16/2851 , C07K16/18 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/6872
摘要： The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
摘要翻译： 本发明涉及能够特异性结合凝集素样转录物1（LLT1）的单克隆抗体，编码这种抗体的多核苷酸和表达这种抗体的细胞。 本发明的抗体可用于治疗自身免疫疾病和癌症，其中表达LLT1和CD161的细胞在疾病发病中起作用。
-
公开(公告)号：US09127052B2
公开(公告)日：2015-09-08
申请号：US13807505
申请日：2011-06-28
申请人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
发明人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
CPC分类号： C07K16/2851 , C07K16/18 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/6872
摘要： The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.
摘要翻译： 本发明涉及能够特异性结合凝集素样转录物1（LLT1）的单克隆抗体，编码这种抗体的多核苷酸和表达这种抗体的细胞。 本发明的抗体可用于治疗自身免疫疾病和癌症，其中表达LLT1和CD161的细胞在疾病发病中起作用。
-
公开(公告)号：US08901283B2
公开(公告)日：2014-12-02
申请号：US13477888
申请日：2012-05-22
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2851 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.
摘要翻译： 本文描述了适用于人类治疗的抗NKG2A抗体，包括鼠抗NKG2A抗体Z270的人源化形式，以及用于产生和使用该抗体的相关方法和材料。 还描述了示例性互补决定区（CDR）序列和用于此类抗体的框架区（FR）和/或CDR中任选氨基酸反向取代的位点。
-
公开(公告)号：US20080274047A1
公开(公告)日：2008-11-06
申请号：US12089314
申请日：2006-10-13
申请人： Francois Romagne , Alessandro Moretta , Mathieu Blery , Petrus Johannes Louis Spee , Ulrik Morch
发明人： Francois Romagne , Alessandro Moretta , Mathieu Blery , Petrus Johannes Louis Spee , Ulrik Morch
IPC分类号： A61K51/00 , A61K39/395 , C07K16/18 , G01N33/569 , A61P37/00
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/2851
摘要： The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
摘要翻译： 本发明涉及治疗增殖性疾病，特别是免疫增殖性和自身免疫性疾病的方法，以及产生结合NK细胞受体的抗体的方法，用于治疗这些病症的治疗策略，特别是耗尽参与免疫增殖性病理学的细胞。
-
公开(公告)号：US08796427B2
公开(公告)日：2014-08-05
申请号：US12811990
申请日：2009-01-23
申请人： Petrus Johannes Louis Spee , Jianhe Chen , Søren Berg Padkjær , Jing Su , Jinchao Zhang , Jiujiu Yu
发明人： Petrus Johannes Louis Spee , Jianhe Chen , Søren Berg Padkjær , Jing Su , Jinchao Zhang , Jiujiu Yu
IPC分类号： C07K16/28
CPC分类号： C07K16/2851 , C07K16/2803 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.
摘要翻译： 本发明涉及作为CD94 / NKG2A受体的非竞争性拮抗剂如某些抗NKG2A抗体，特别是鼠抗NKG2A抗体Z199的人源化形式的试剂，以及制备和使用这些试剂和抗体的方法 。
-
公开(公告)号：US20100247526A1
公开(公告)日：2010-09-30
申请号：US12305683
申请日：2007-06-28
IPC分类号： A61K39/395 , A61P35/00 , A61P29/00 , C07K16/28 , C12P21/04
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2851 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.
摘要翻译： 本文描述了适用于人类治疗的抗NKG2A抗体，包括鼠抗NKG2A抗体Z270的人源化形式，以及用于产生和使用该抗体的相关方法和材料。 还描述了示例性互补决定区（CDR）序列和用于此类抗体的框架区（FR）和/或CDR中任选氨基酸反向取代的位点。
-
公开(公告)号：US20090281035A1
公开(公告)日：2009-11-12
申请号：US12305678
申请日：2007-06-22
申请人： Petrus Johannes Louis Spee , Soren Berg Padkaer , Birgitte Nissen Friedrichsen , Inga Sig Nielsen Norby
发明人： Petrus Johannes Louis Spee , Soren Berg Padkaer , Birgitte Nissen Friedrichsen , Inga Sig Nielsen Norby
IPC分类号： A61K38/17 , C07K14/705 , C07K16/00 , C12P21/02
CPC分类号： C12N15/62 , C07K14/7056 , C07K14/70596 , G01N2333/70596
摘要： Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each receptor monomer, and some constructs further comprise at least one immunoglobulin Fc domain. Exemplary constructs are those wherein (1) each soluble fragment is linked to an immunoglobulin Fc domain, which are then allowed to dimerize, (2) each soluble fragment is linked to an immunoglobulin Fc domain mutated to promote forced dimerization with the correct counterpart, and (3) single-chain constructs where the monomeric receptor fragments are linked, and the C-terminal fragment is linked to an Fc domain.
摘要翻译： 描述了异二聚体受体的可溶性形式，例如CD94 / NKG2受体，以及生产和使用这些构建体的方法。 构建体包含每个受体单体的可溶性片段，并且一些构建体还包含至少一个免疫球蛋白Fc结构域。 示例性构建体是其中（1）每个可溶性片段连接到免疫球蛋白Fc结构域，然后允许其二聚化，（2）每个可溶性片段连接到突变的免疫球蛋白Fc结构域以促进与正确对应物的强制二聚化，以及 （3）其中连接单体受体片段的单链构建体，并且C-末端片段连接于Fc结构域。
-
公开(公告)号：US09447185B2
公开(公告)日：2016-09-20
申请号：US12089314
申请日：2006-10-13
申请人： Francois Romagne , Alessandro Moretta , Mathieu Blery , Petrus Johannes Louis Spee , Ulrik Morch
发明人： Francois Romagne , Alessandro Moretta , Mathieu Blery , Petrus Johannes Louis Spee , Ulrik Morch
IPC分类号： A61K39/395 , A61K39/00 , A61K39/38 , C07K16/28
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2803 , C07K16/2851
摘要： The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.
摘要翻译： 本发明涉及治疗增殖性疾病，特别是免疫增殖性和自身免疫性疾病的方法，以及产生结合NK细胞受体的抗体的方法，用于治疗这些疾病的治疗策略，特别是消耗参与免疫增殖性病理学的细胞。
-
公开(公告)号：US20120237510A1
公开(公告)日：2012-09-20
申请号：US13477888
申请日：2012-05-22
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2851 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.
摘要翻译： 本文描述了适用于人类治疗的抗NKG2A抗体，包括鼠抗NKG2A抗体Z270的人源化形式，以及用于产生和使用该抗体的相关方法和材料。 还描述了示例性互补决定区（CDR）序列和用于此类抗体的框架区（FR）和/或CDR中任选氨基酸反向取代的位点。
-
公开(公告)号：US08206709B2
公开(公告)日：2012-06-26
申请号：US12305683
申请日：2007-06-28
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2851 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.
摘要翻译： 本文描述了适用于人类治疗的抗NKG2A抗体，包括鼠抗NKG2A抗体Z270的人源化形式，以及用于产生和使用该抗体的相关方法和材料。 还描述了示例性互补决定区（CDR）序列和用于此类抗体的框架区（FR）和/或CDR中任选氨基酸反向取代的位点。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.035 秒)